Summary of studies on GSTT1 status and the risk of head and neck cancer
| Author | Country | Cases | %GSTT1 deficiency | Controls | %GSTT1 deficiency | Control source | Tumour sites | Power (RR⩾1.5, α = 0.05) | Power (RR⩾2, α = 0.05) |
|---|---|---|---|---|---|---|---|---|---|
| Trizna et al, 1995 11 | USA | 127 | 44.9% | 42 | 35.7% | population | head and neck | 19% | 47% |
| Deakin et al, 1996 13 | UK | 34 | 11.8% | 509 | 18.5% | hospital | oral cavity | 16% | 45% |
| Jahnke et al, 1996 14 | Germany | 269 | 20.8% | 146 | 19.2% | not available | larynx | 26% | 80% |
| Hung et al, 1997 15 | Taiwan | 41 | 58.5% | 123 | 52.8% | population | oral cavity | 19% | 46% |
| Oude Ophuis et al, 1998 17 | Netherlands | 185 | 19.5% | 207 | 20.3% | population | head and neck | 40% | 85% |
| Matthias et al, 1998 20 | Germany | 263 | 19.4% | 203 | 22.2% | hospital | larynx | 46% | 90% |
| Matthias et al, 1998 20 | Germany | 122 | 27.7% | 203 | 22.2% | hospital | oral/pharynx | 36% | 78% |
| Jourenkova et al, 1998 21 | France | 129 | 19.4% | 172 | 15.7% | hospital | larynx | 27% | 68% |
| Cheng et al, 1999 24 | USA | 162 | 32.7% | 315 | 17.5% | population | head and neck | 41% | 86% |
| Jourenkova-Mironova et al, 1999a 25 | France | 67 | 22.4% | 172 | 15.7% | hospital | oral cavity | 14% | 35% |
| Jourenkova-Mironova et al, 1999a 25 | France | 50 | 52.0% | 172 | 52.3% | hospital | pharynx | 23% | 53% |
| Katoh et al, 1999 27 | Japan | 92 | 47.8% | 147 | 51.0% | population | oral cavity | 27% | 71% |
| Hong et al, 2000 30 | Korea | 82 | 57.3% | 63 | 36.5% | hospital | larynx | 28% | 52% |
| McWilliams et al, 2000 31 | USA | 142 | 16.9% | 109 | 18.3% | population | head and neck | 25% | 62% |
| Hamel et al, 2000 6 | Canada | 90 | 22.2% | 90 | 10.0% | hospital | head and neck | 24% | 45% |
| Olshan et al, 2000; 5 African-American | USA | 63 | 77.8% | 25 | 80.0% | hospital | head and neck | 10% | 19% |
| Olshan et al, 2000; 5 white | USA | 109 | 16.5% | 168 | 12.5% | hospital | head and neck | 22% | 57% |
| Kietthubthew et al, 2001 7 | Thailand | 53 | 34.0% | 53 | 47.2% | population | oral cavity | 17% | 41% |
| Sreelekha et al, 2001 32 | India | 98 | 18.4% | 45 | 11.1% | population | oral cavity | 20% | 71% |
| Cabelguenne et al, 2001 33 | France | 162 | 17.9% | 264 | 19.3% | hospital | head and neck | 40% | 86% |
| Ko et al, 2001 34 | Germany | 312 | 20.5% | 300 | 20.3% | population | head and neck | 56% | 96% |
| Buch et al, 2002 36 | India | 297 | 18.2% | 450 | 12.2% | population | oral cavity | 50% | 93% |
| To-Figueras et al, 2002 37 | Spain | 204 | 17.2% | 203 | 23.6% | population | larynx | 44% | 89% |
| Cheng et al, 2003 39 | Taiwan | 316 | 50.6% | 336 | 51.8% | population | pharynx | 72% | 98% |
| Risch et al, 2003 4 | Germany | 245 | 15.5% | 251 | 13.9% | population | larynx | 39% | 84% |
| Gronau et al, 2003a 40 | Germany | 73 | 15.1% | 136 | 14.0% | hospital | oral cavity | 20% | 30% |
| Gronau et al, 2003b 41 | Germany | 187 | 16.0% | 139 | 15.1% | population | head and neck | 27% | 67% |